# Peptide evidence grading

Rating: Speculative — Little primary evidence yet: mechanism, anecdote or tradition
Type: Method
Updated: 2026-08-06
Canonical: https://heretic.bio/articles/peptide-evidence-grading-framework.html

> This is a method note, not a therapy: a five-tier evidence scale running from human randomized trials down to anecdote, combined with a regulatory tier running from FDA-approved to prohibited. Applied to mid-2026 examples, most gray-market peptides land at Tier 3-4, meaning animal or mechanistic data only, while their regulatory status shifted with the April 2026 Category 2 removal and the July 2026 PCAC reviews. It is a proposed framework for sorting claims, not a clinical tool.

## Rationale

Peter Attia’s AMA #83 (April 2026) introduced numerical evidence grades for peptides (e.g., BPC-157: 9/10). Combined with the April 2026 FDA reclassification of 12 peptides from Category 2 (removing "significant safety concerns" designation) and the July 23-24, 2026 PCAC review of seven peptides for 503A Bulks List eligibility, there is clear market demand for a standardized, rigorous evidence grading framework that integrates both scientific evidence and regulatory status.

## Proposed Framework

### Evidence Tiers (Scientific)

  * **Tier 1** : Human RCT or systematic review/meta-analysis (highest quality human data)
  * **Tier 2** : Human observational studies, cohort, case-control
  * **Tier 3** : Animal (in vivo) studies
  * **Tier 4** : In-vitro or mechanistic studies
  * **Tier 5** : Anecdote, marketing claims, or expert opinion only



### Regulatory Tiers (2026 Status)

  * **FDA-approved** : Approved drug product
  * **Compounding-available (Category 1 post-review)** : Eligible for 503A compounding if added to Bulks List
  * **Restricted/Gray-market (Category 2 removed; under PCAC review)** : Previously restricted; now under formal evaluation (e.g., BPC-157, TB-500, Epitalon as of July 2026)
  * **Prohibited** : Category 2 with safety concerns upheld or withdrawn nominations not advancing



### Composite Risk Profile

Evidence tier + Regulatory tier = Operator risk score (for telehealth/clinic protocol design and investor diligence).

## Applied Examples (Updated with 2026 Regulatory Context)

  * **BPC-157** : Evidence Tier 3 (primarily animal + limited human); Regulatory: Category 2 removed April 2026 → PCAC review July 23, 2026 (ulcerative colitis indication). Composite: Moderate-high risk pending PCAC outcome.
  * **2026 PCAC Meeting (July 23-24)** : FDA Pharmacy Compounding Advisory Committee reviewed 7 peptides for 503A Bulks List eligibility:
  * July 23: BPC-157 (UC), KPV, TB-500, MOTS-C (obesity/osteoporosis)
  * July 24: Emideltide/DSIP (opioid withdrawal), Semax (ischemia/migraine), Epitalon (insomnia) Outcomes pending as of July 25, 2026; no final Bulks List additions announced. Human evidence flagged as limited/scant for most (small/uncontrolled studies); safety signals noted (e.g., Epitalon telomerase/carcinogenicity concerns, Semax anticoagulant effects). [FDA Peptide Reclassification 2026 — Regulatory Intelligence](fda-peptide-reclassification-2026.html)
  * **Rapamycin** : Evidence Tier 2 (human observational + off-label use); Regulatory: Off-label (not bulk compounding restricted).
  * **Epitalon** : Evidence Tier 3-4 (animal/mechanistic, Russian bioregulator data); Regulatory: PCAC review July 24, 2026 (insomnia).
  * **GHK-Cu** : Evidence Tier 3-4; Regulatory: Removed from Category 1 April 2026; follow-up PCAC before Feb 2027.
  * **TB-500 / Thymosin Beta-4** : Evidence Tier 3 (animal wound healing); Regulatory: PCAC July 23, 2026.



**Human vs Animal vs In-Vitro Separation Required** in all applications: Prioritize Tier 1-2 human data; flag Tier 3+ for additional disclaimers.

## Use Cases

  * Telehealth protocol design and patient selection
  * Clinic patient education materials
  * Content creation and claims substantiation
  * Investor due diligence on compounding/telehealth valuations
  * Post-PCAC scenario planning (July 2026 outcomes)



## Personalization Angles

  * Peter Attia / The Drive (evidence grading)
  * Gary Brecka / 10X Health
  * Andrew Huberman (mechanism focus)
  * Nava Health, Ways2Well, HealingMaps (practitioners)
  * Integration with 01 - Peptides/FDA Peptide Reclassification 2026 — Regulatory Intelligence

## Sources